Abstract
Hepatitis C is the leading cause of progressive liver fibrosis worldwide and results in cirrhosis, liver cancer, liver failure and death. Successful treatment for hepatitis C virus (HCV) has rapidly evolved in recent years to a well-tolerated, highly efficacious all-oral therapy. Elbasvir/grazoprevir (Zepatier) is the newest of the oral combinations of HCV direct-acting agents that was approved by the US Federal Drug Administration. This review focuses on the pharmacology, mechanism of action and clinical trial data that support the use of this new combination treatment for HCV infection. The data suggest that Zepatier offers an excellent treatment efficacy, safety and tolerability in HCV treatment naïve and experienced patients and those with and without cirrhosis across multiple genotypes. Also, it has the selective advantage of safety and efficacy in patients with renal disease, especially in those with end-stage renal disease and/or hemodialysis patients.
Similar content being viewed by others
References
Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3(2):47–52
Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int 2015;9(2):161–173
Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012;56(8):4161–4167
Harper S, McCauley JA, Rudd MT, et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 2012;3(4):332–336
Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. Chem Med Chem 2013;8(12):1930–1940
Xue W, Ban Y, Liu H, Yao X. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. J Chem Inf Model 2014;54(2):621–633
Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, et al. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Chemother 2016;60:2954–2964
Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol WJG 2014;20(11):2902–2912
Brainard DM, et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in healthy subjects. Hepatology 2010;52(4)
Food and Drug Administration. Highlights of prescribing information. Available at https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed 23 March 2016
Yeh WW, Caro L, Guo Z, et al. Pharmacokinetics of co-administered HCV protease inhibitor MK-5172 and NS5A inhibitor MK-8742 in volunteers with end-stage renal disease on hemodialysis or severe renal impairment not on hemodialysis. Hepatology 2014;60(4 Suppl 1):1137A
Marshall W, Yeh W, Stypinski D, et al. No evidence of pharmacokinetic drug-drug interaction in healthy subjects between co-administered grazoprevir (MK-5712)/elbasvir (MK-8742) and sofosbuvir [Abstract P0910]. 50th Annual Meeting of the EASL, Vol 62 June 2015 Issue
Caro L, Anderson M, Du L, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship for MK-5172, a novel hepatitis C virus (HCV) NS3/4A protease inhibitor, in genotype 1 and genotype 3 HCV-infected patients: The 62nd Annual Meeting of the AASLD, San Francisco, Nov 5–11, 2011
Yeh W, Marshall W, Mangin E, et al. Pharmacokinetic interactions between the HCV NS5A inhibitor MK-8742 and efavirenz [abstract 498]. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, March 3–6, 2014
Yeh WY, Marshall W, Ma J, et al. Ritonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels [abstract 635]. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, March 3–6, 2014
Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385(9973):1075–1086
Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385(9973):1087–1097
Gane E, Nahass R, Luketic V, et al. P0776: efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients. J Hepatol 2015;62:S621
Asante-Appiah E, Liu R, Curry S, et al. MK-8408, a potent and selective NS5A inhibitor with a high genetic barrier to resistance and activity against HCV genotypes 1–6. Conference Reports for the NATAP: The 65th Annual Meeting of the AASLD. Boston, Nov 7–11, 2014
Forns X, Gordon S, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015;63(3):564–572
Buti M, Gordon S, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE: table 1. Clin Infect Dis 2015;62(1):32–36
Lagging M, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, et al. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat 2016;23:80–88
Brown A, Hezode C, Zuckerman E, et al. P0771 : C-SCAPE: efficacy and safety of 12 weeks of grazoprevir ± elbasvir ± ribavirin in patients with HCV GT2, 4, 5 or 6 infection. J Hepatol 2015;62:S619
Poordad F, Lawitz E, Gutierrez J, et al. O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks. J Hepatol 2015;62:S192–S193
Special reporting on: C-SWIFT: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks PLUS meeting abstract summaries with expert commentary by: Steven L. Flamm. Gastroenterol Hepatol 2015;11(6 Suppl 3):1–23
Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014;147(2):366–376
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1–13
Rockstroh J, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2(8):e319–e327
Kwo P, Gane E, Peng C, et al. P0886: efficacy and safety of grazoprevir/elbasvir ± RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial. J Hepatol 2015;62:S674–S675
Kwo P, Gane E, Peng C, et al. 901f efficacy and safety of grazoprevir/elbasvir ± ribavirin (RBV) for 12 or 16 weeks in patients with HCV G1, G4, or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial. Gastroenterology 2015;148(4):S-1194–S-1195
Roth D, Nelson D, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386(10003):1537–1545
Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312(4):353–361
Jacobson IM, Poordad F, Firpi-Morell R. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT part A). J Hepatol 2015;62:S193
Kwo P, Gane E, Peng CY, et al. Efficacy and safety of grazoprevir/elbasvir ± RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial [Abstract PO886]. 50th Annual Meeting of the EASL. Vienna, April 22–26, 2015b
Acknowledgements
All authors critically reviewed the manuscript and approve the final version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding was used for the preparation of this paper.
Conflict of interest
The authors declare that there is no conflict of interest regarding the publication of this manuscript.
Ethical compliance
None. No human subjects were enrolled for this manuscript.
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s12072-016-9781-y.
Rights and permissions
About this article
Cite this article
Papudesu, C., Kottilil, S. & Bagchi, S. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatol Int 11, 152–160 (2017). https://doi.org/10.1007/s12072-016-9761-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-016-9761-2